Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bayer ( (DE:BAYN) ) has issued an update.
Bayer disclosed a managers’ transaction involving The Herbert-Schechter Trust, which is closely associated with supervisory board member Lori Schechter, purchasing Bayer shares. The transaction, executed on March 6, 2026 via Xetra, totaled €71,630 at a price of €37.70 per share, reflecting the Supervisory Board members’ commitment to buy Bayer stock and signaling continued insider confidence in the company.
The purchase forms part of Bayer’s structured share-buying commitments for supervisory board members, aligning board interests more closely with those of shareholders. Such insider acquisitions can be viewed positively by investors, as they often indicate long-term commitment from the company’s governance bodies and may influence market perception of Bayer’s valuation and strategic outlook.
The most recent analyst rating on (DE:BAYN) stock is a Buy with a EUR48.00 price target. To see the full list of analyst forecasts on Bayer stock, see the DE:BAYN Stock Forecast page.
More about Bayer
Bayer Aktiengesellschaft is a German life sciences company focused on healthcare and agriculture, with core businesses in pharmaceuticals, consumer health products, and crop science. Its shares are listed on major regulated markets in Germany, including Frankfurt and Xetra, under ISIN DE000BAY0017.
YTD Price Performance: -1.68%
Average Trading Volume: 3,861,126
Technical Sentiment Signal: Sell
Current Market Cap: €35.75B
See more data about BAYN stock on TipRanks’ Stock Analysis page.